Acute coronary syndromes
BA Bergmark, N Mathenge, PA Merlini… - The Lancet, 2022 - thelancet.com
Although substantial progress has been made in the diagnosis and treatment of acute
coronary syndromes, cardiovascular disease remains the leading cause of death globally …
coronary syndromes, cardiovascular disease remains the leading cause of death globally …
Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update
CYP2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19
genotype impacts clopidogrel active metabolite formation. CYP2C19 intermediate and poor …
genotype impacts clopidogrel active metabolite formation. CYP2C19 intermediate and poor …
[HTML][HTML] Antiplatelet therapy after percutaneous coronary intervention
Antiplatelet therapy is key to reducing local thrombotic complications and systemic
ischaemic events among patients undergoing percutaneous coronary interventions (PCI) …
ischaemic events among patients undergoing percutaneous coronary interventions (PCI) …
Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the …
NL Pereira, ME Farkouh, D So, R Lennon, N Geller… - Jama, 2020 - jamanetwork.com
Importance After percutaneous coronary intervention (PCI), patients withCYP2C19* 2or*
3loss-of-function (LOF) variants treated with clopidogrel have increased risk of ischemic …
3loss-of-function (LOF) variants treated with clopidogrel have increased risk of ischemic …
2018 ESC/EACTS Guidelines on myocardial revascularization
FJ Neumann, M Sousa-Uva, A Ahlsson… - European heart …, 2019 - academic.oup.com
always refer to the full text version, which is freely available on the ESC and EACTS
websites. The National Societies of the ESC are encouraged to endorse, translate, and …
websites. The National Societies of the ESC are encouraged to endorse, translate, and …
Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis
Background Whether guided selection of antiplatelet therapy in patients undergoing
percutaneous coronary intervention (PCI) is effective in improving outcomes compared with …
percutaneous coronary intervention (PCI) is effective in improving outcomes compared with …
Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary …
Dual-antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the standard
treatment for patients undergoing percutaneous coronary intervention. The availability of …
treatment for patients undergoing percutaneous coronary intervention. The availability of …
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy …
Guidelines, Aspirin, Clopidogrel, Ticagrelor, Prasugrel, Dual antiplatelet therapy, Acute
coronary syndromes, Coronary artery bypass grafting, Coronary artery disease, Drug-eluting …
coronary syndromes, Coronary artery bypass grafting, Coronary artery disease, Drug-eluting …
A brief review of cardiovascular diseases, associated risk factors and current treatment regimes
Cardiovascular diseases (CVDs) are the leading cause of premature death and disability in
humans and their incidence is on the rise globally. Given their substantial contribution …
humans and their incidence is on the rise globally. Given their substantial contribution …
A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI
DMF Claassens, GJA Vos, TO Bergmeijer… - … England Journal of …, 2019 - Mass Medical Soc
Background It is unknown whether patients undergoing primary percutaneous coronary
intervention (PCI) benefit from genotype-guided selection of oral P2Y12 inhibitors. Methods …
intervention (PCI) benefit from genotype-guided selection of oral P2Y12 inhibitors. Methods …